Further data from study 014/015 of evenamide in treatment-resistant schizophrenia confirms potentially relevant role of glutamatergic release modification when added to TRS patients not responding. | May 3, 2023
maximally sustaining IL-6 suppression in a chronic disease like NMOSD and enabling subcutaneous dosing every four weeks. Positive Phase III results for ENSPRYNG, as both monotherapy and in. | March 25, 2022
First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presentedEvrysdi data continue